ME/CFS Science @mecfsscience.org · 14/07/20263) After activation, some HERV-W sequences produce an envelope protein ("ENV") that the immune system reacts badly to. Temelimab binds to this protein to make sure it no longer acts as a false alarm for the immune system. 160
ME/CFS Science @mecfsscience.org · 14/07/20264) There were a couple of Long Covid studies that reported increased HERV-W ENV in Long Covid patients. This trial therefore used this as an inclusion criterion in their trial. It focused only on LC patients who were positive for HERV-W ENV in their blood. 150
ME/CFS Science @mecfsscience.org · 14/07/20265) This was a large placebo-controlled and international trial: it recruited 203 patients from three European countries (Switzerland, Italy, and Spain) involving 14 centers. The primary outcome was the PROMIS Fatigue SF 7a scale. 150
